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                                      INTRODUCTION 
                    Eyelid is a complex structure and the multitude of  tumors 
arising from it are classified according to the eyelid structures from 
which the arise. These tumors differ from other coetaneous lesions 
because of  the unique characteristics of eyelid skin. 
                   Accuracy in diagnosis requires an awareness of the many 
different lesions, familiarity with practical classification and accurate 
histopathological examination. The accurate diagnosis is of  great value 
in deciding the appropriate treatment. 
                  Treatment modalities of lid tumors are plenty but surgery has 
been primarily described for most tumors. Most errors in the 
management of lid tumors are the result of inaccurate diagnosis, lack of 
appropriate histological studies or due to inadequate surgical margins.                 
                  Ophthalmic diseases rarely threaten life, however there are 
certain eyelid tumors that have propensity for aggressive growth and life 
threatening metastasis. 
 
  
                           ANATOMY OF THE EYELIDS 
                   A thorough knowledge of eyelid anatomy is essential for 
a surgeon who performs lid reconstruction. The tissues of the eyelid 
from anterior to posterior are described as follows.  
• Skin and subcutaneous tissue 
• Muscles of protraction  
• Fibrous layer including tarsal plate  
• Muscles of retraction 
• Conjunctiva     
SKIN 
               Eyelid skin is the thinnest of the body without subcutaneous 
fat. Skin is made of stratified squamous epithelium. At the lid margin 
the skin is continuous with the conjunctiva at the greyline. There are 
100 to 150 cilia in the upper lid and 50 in the lower lid.  
 
 
ORBICULARIS OCULI 
                 It is the main protractor of the eyelid. Contraction of this 
muscles narrows the palpebral fissure. It is divided into pretarsal, 
 preseptal, orbital parts. Palpebral part is confined to the lids and 
arises from the medial canthal tendon and is inserted into the lateral 
canthal tendon and lateral orbital tubercle. Pars lacrimalis (tensor 
tarsi muscle) arises from posterior lacrimal crest and inserted into 
medial border of tarsal plate. Pars ciliaris(muscle of Riolan) is an 
isolated fasciculus of  fine muscle running along lid margin.  
TARSAL PLATES AND CANTHAL TENDONS 
                   Tarsal plates are firm dense plates of fibrous tissue 
without cartilage that serve as the internal skeleton of the lid. 
Superior tarsus is D shaped measuring 10 to 12 mm in height the 
midline. Inferior tarsus is oblong  4mm in height. Both are 1mm thick 
and their ends taper at the medial and lateral ends. 
                  The medial canthal tendon arises from anterior and 
posterior lacrimal crest and it splits temporal to the lacrimal sac into 
an upper limb and a lower limb that attach to the upper and lower 
tarsal plates. 
                   The lateral canthal tendon is about 7mm long, attached to 
the lateral orbital tubercle. It splits into superior and inferior branches 
that attach to the respective tarsal plates. 
MUSCLES OF RETRACTION 
                   Levator palpebrae superioris originates from the lesser 
wing of sphenoid .The muscular portion is 40mm long. The 
aponeurosis is 15mm long coursing downwards to insert into anterior 
surface of tarsus. 
                 Mullers muscle originates at the undersurface of the 
levator and inserts into the upper tarsal border. It is sympathetically 
innervated. 
                  The capsulopalpebral fascia in the lower lid is analogous 
to the levator of the upper lid. It arises from the terminal muscle 
fibres of the inferior rectus and insert onto the lower tarsal border. 
CONJUNCTIVA 
                It is composed of nonkeratinising squamous epithelium. It 
contains the mucin secreting goblet cells and the accessory lacrimal 
glands. 
GLANDS OF THE EYELIDS 
                  External skin of the lid contains small sweat and 
sebaceous glands, in addition it contains large modified sebaceous 
glands embedded in the tarsus. The meibomian glands number 
approximately 20 to 25 in each tarsal plate. The are elongated tubular 
structure with their ducts opening into the lid margin. Their acini 
 show the usual picture of  sebaceous glands, polyhedral cells loaded 
with cebum. The ducts are lined with stratified squamous epithelium 
which develop keratinization near their termination. Meibomian 
secretion is pale yellow in colour. 
                The glands of Zeis are also modified sebaceous glands 
opening into the follicles of cilia. The glands of Moll are simple 
sweat glands situated near the lid margins and in close association 
with Zeis glands. The glands of Krause and Wolfring are accessory 
lacrimal glands numbering 2 to 3 in each lid.  
BLOOD SUPPLY OF THE EYELIDS 
       ARTERIES 
                  The blood supply to the lids is derived mainly from 
medial and lateral palpebral branches of the ophthalmic and lacrimal 
artery. Branches of these vessels form the tarsal arches, two in the 
upper lid and one in the lower lid. Marginal artery passes 3mm from 
the lid margin between tarsal plate and orbicularis. 
 
VEINS 
                 The superior and inferior palpebral arcades drain into the 
angular vein of medial canthus. Angular vein drains into the internal 
 jugular vein. Post tarsal drainage is into the orbital veins, anterior 
facial vein.  
LYMPHATIC DRAINAGE 
                       The lymphatics are arranged in pre and post tarsal 
plexus connected by cross channels. The post tarsal plexus drains 
conjunctiva and tarsal glands. The pretarsal plexus drains the skin. 
Lateral portion of lid drains into the preauricular and deep cervical 
nodes while those from medial side drain into submandibular lymph 
nodes. 
NERVE SUPPLY 
MOTOR 
                       The orbicularis occuli is supplied by the facial nerve, 
the levator by the occulomotor nerve. Mullers muscle is supplied by 
post ganglionic sympathetic nerve fibres. 
 
 
 
SENSORY 
                         Upper lid is supplied by supraorbital nerve, lacrimal 
nerve, branches of the ophthalmic division of the trigeminal nerve. 
 The lower lid is supplied by the infraorbital nerve, branch of 
maxillary division of trigeminal nerve.  
      
FUNCTIONS OF THE EYELIDS 
                             The protective system of the eyelids are mediated by 
the following. 
• The screening and sensing action of the cilia 
• The secretions of the meibomian glands, Zeis glands form the 
superficial lipid layer of tear film, the middle aquous layer is 
formed by fluid secreted from the accessory lacrimal glands. 
• The third important element is the closure of eyelids by the action 
of orbicularis occuli. Types of  lid closure are affected by different 
combinations of fibre bundle action of orbicularis. 
               CLASSIFICATION OF LID TUMORS 
                                   Duke Elder has classified tumors of the eyelid into 
eight categories 
1. EPITHELIAL TUMORS 
a. Cutaneous  
Benign-   Papilloma, senile keratosis, keratoacanthoma, seborrheic 
keratosis, 
 inverted follicular keratosis, trichoepithelioma, benign calcifying 
epithelioma. 
Malignant-  Squamous cell epithelioma, basal cell epithelioma, 
intraepithelial carcinoma, xeroderma pigmentosa. 
b. Glandular 
Tumors of sebaceous glands- Adenoma of the meibomian, Zeis glands 
                                                  Adenocarcinoma of meibomian, Zeis 
glands 
Tumors of sweat glands- Hidradenoma of skin- syringoma, pleomorphic 
      adenoma                 
                                           Hidradenocarcinoma of skin, Moll’s glands 
Papillary cystadenoma lymphomatosum 
Oncocytoma 
 
 
2. MESENCHYMAL TUMORS 
Benign- Fibroma, tuberous sclerosis, lipoma, rhabdomyoma, leiomyoma, 
myxoma.                                                                                                        
Malignant- Sarcoma.  
3. TUMORS OF THE LYMPHORETICULAR TISSUE 
Benign lymphoma, lymphosarcoma, reticulum sarcoma, giant 
follicular sarcoma, Burkitt lymphoma, mycosis fungoides, plasmacytoma 
4. VASCULAR TUMORS 
 Hemangioma- Capillary, cavernous, plexiform, hemangioendothelioma,  
                           Hemangiopericytoma, spiderangioma, senile angioma 
Telangiectatic granuloma 
Angioteratoma of Mibelli 
Multiple hemorrhagic sarcoma of Kaposi 
Glomus tumor 
Lymphangioma, lymphangioendothelioma 
 
 
5. NERVOUS TISSUE TUMORS 
Neurofibromatosis- Plexiform, diffuse, molluscum fibrosum, multiple 
mucosal     
                        neuroma syndrome 
Neurilemmoma 
Ganglioneuroma 
Granular cell Schwannoma of Abrikossoff 
6. PIGMENTED TUMORS 
Nevus 
Malignant melanoma 
7. METASTATIC CARCINOMA 
 8. DEVOLOPMENTAL TUMORS 
Dermoids 
Teratoma 
Phakomatos choristoma 
                  BENIGN TUMORS OF THE EYELIDS 
PAPILLOMA 
                        These common tumors usually appear on the lid margins 
as raspberry like growths or pedunculated lesions. Histologically the 
show acanthosis and parakeratosis with fibrovascular dermal component. 
Treatment is by shave excision at the dermal- epidermal junction 
SEBORRHEIC KERATOSIS 
                         They are the most common acquired benign papilloma 
affecting the middle age and elderly patients. They have a lobulated, 
papillary or pedunculated appearance with visible excrescences. 
Histologically they show an acanthotic proliferation of  basaloid cells. 
These lesions must be differentiated from basal cell  carcinoma, nevi, 
actinic keratosis. 
                          The prefered technique of removal is by shaving the 
lesion at the dermal- epidermal junction. 
 
  
 
 
FIBROEPITHELIAL PAPILLOMA  
                           Commonly known as ‘skin tags’, these lesions appear as 
skin coloured, smooth filiform papules. They are often multiple in 
number found at the lid margins. Histologically they show proliferation 
of epithelium with hyperkeratosis around a central fibrous core. 
Treatment is by simple excision under local anaesthesia. 
WARTS 
                        There are two types of verrucae found on the eyelid- 
verruca                                                                                                                                          
vulgaris and verruca planus. Both are caused by human papilloma virus. 
Prefered treatment is cryotherapy and light desiccation under local 
anaesthesia. 
INCLUSION CYST(SEBACEOUS CYST) 
                         These are the second most common benign cutaneous 
lesions. These arise from the infundibulum of the hair follicle, either 
spontaneously or following trauma. These lesions are slow growing, 
 elevated, round, smooth tumors with central pore. Although referred to as 
sebaceous cysts they are actually filled with keratin. 
                           Recommended treatment for small cyst is 
marsupialisation, larger cyst need complete excision of cyst wall. 
MOLLUSCUM CONTAGIOSUM 
                           These are skin coloured papules 2-4mm in size with an 
umbilicated centre. They are of viral etiology. They are best treated by 
cryotherapy or by light desiccation. 
SYRINGOMA  
                       Benign eccrine sweatgland tumors presenting as multiple, 
small, waxy, pale yellow nodules 1-2mm in diameter in the lower 
eyelids. They are common in young females. Because of their dermal 
location they need deep excision in a staged fashion.  
APOCRINE HIDROCYSTOMA 
                       It is a true adenoma of the secretory cells of the glands of 
Moll. These lesions are translucent, found in the lid margin. Treatment is 
marsupialisation. They are also known as cystadenomas. 
MELANOCYTIC NEVI 
                       Nevi are the third most common benign lesions after 
papillomas and sebaceous cyst. They arise from incompletely 
 differentiated melanocytes found in the epidermis, dermis, junctional 
zone. All nevi undergo evolution through three stages. 
                       Junctional nevi are located in the basal layer of epidermis 
at the dermal- epidermal junction. Compound nevi extend from the 
junctional zone into the epidermis and dermis. Dermal nevi have 
involution of  the epidermal component with persistent dermal 
component.  
                       They require no treatment, but malignant transformation of 
the compound or junctional nevus rarely occurs. 
ACTINIC KERATOSIS 
                     It is the most precancerous skin lesion affecting elderly 
individuals. They are typically round, scaly plaques with the texture of  
sand paper. Treatment is with incisional or excisional biopsy, 
cryodestruction, topical 5- flurouracil. 
KERATOACANTHOMA 
                    It is considered to be a low grade squamous cell carcinoma. 
It begins as a papule on the lower lid that develops into a dome shaped 
nodule with a central keratin filled crater with rolled margins. Complete 
surgical excision is the treatment of choice. 
 
  
HEMANGIOMA 
                     These are hamartomas. Capillary hemangiomas are 
primarily seen in children, often appearing in the first week of life and 
enlarging till one year of age. After one year they begin to involute. They 
are more common in the medial upper eyelids and have high blood flow 
derived from multiple feeder vessels. 
                      Treatment options include observation, oral prednisolone, 
local steroid injection, systemic interferon alfa, radiotherapy, surgery. 
                      Cavernous hemangiomas are common in middle aged 
women usually associated with proptosis. They are encapsulated tumors. 
                       Lymphangiomas are relatively uncommon tumors that may 
involve the eyelids rarely. These tumors have serum filled spaces lined 
with endothelial cells. They may suddenly enlarge insize if there is a 
hemrorrhage into the tumor. 
NEUROFIBROMATOSIS 
                        Also known as Von Recklinghausen disease, 
neurofibromatosis type 1 is characterized by hamartomas involving the 
skin, eye, CNS.  
                         Plexiform neurofibroma which frequently involve the 
lateral upper eyelid giving a S shaped contour are due to proliferation of 
Schwann cells. 
                        Fibroma molluscum are pedunculated skin nodules 
composed of connective tissue elements. If these lesions become 
unsightly surgical removal is done with plastic reconstructions. 
 
DERMOID 
                         They are congenital in origin becoming apparent in late 
childhood. It presents as a smooth painless mass in the medial upper 
eyelid. They frequently have a dumbbell extension into the orbit. 
Superficial Dermoids are removed through a eye lid crease incision with 
intact cyst wall 
           
 
 
 
 
 
 MALIGNANT TUMORS OF THE EYELID 
                       Lid malignancies are quiet common, most often 
develop in sun exposed people. Approximately 9-15% of cutaneous 
malignancies involve the lid. In the periorbital region basal cell 
carcinoma is the most common cutaneous malignancy. 
                            Malignant lesions can mimic a number of  benign 
conditions and usually require biopsy to determine their nature. As a 
general rule clinical signs suggestive of malignancy include localized 
loss of eyelashes, a pearly telangiectatic change, enlarging lesion, diffuse 
induration, rarely a schirrhous area. 
                            The etiology of carcinoma is exactly unknown but 30% 
of all varieties are found to be associated with trauma or irritation such as 
chronic blepharitis, eczema, injuries like pressure of spectacles, 
radiotherapy. 
BASAL CELL CARCINOMA 
                              Basal cell carcinoma is the most common malignancy 
of  the lid. Over 60% involve the lower eye lid and medial canthus. Least 
commonly involved is the lateral canthus. The average at diagnosis is 60-
80 years and males are more commonly affected. 
                              This malignancy can present as three forms. The most 
common is the nodular pattern which can have an ulcerative pattern or 
multicentric pattern. Histologically tumor cells grow in nests with 
peripheral pallisading. 
                              The morphea form or sclerosing pattern is a flat 
indurated plaque with indistinct borders simulating a blepharitis. Most 
aggressive form with extensive subcutaneous involvement. Histologically 
the tumor cells grow in strands or cords with excess connective tissue 
component. The third rare variant is the clear cell BCC which does not 
present often in eyelids. 
                              Important risk factors for BCC are fair skin colour, 
exposure to UV-B radiation, ionizing radiation. Metastasis are rare and 
they grow very slowly. 
The treatment modalities are 
1.Surgery using microscopic evaluation of margins. Using Moh’s 
technique the recurrence is <6%. When microscopic control is not used 
25% recurrence occurs. 
2. Cryotherapy – Nodular type <10mm size 97% cure rate with 
cryotherapy. 
3. Chemotherapy- Cisplatin, Doxorubicin used for recurrent BCC. 
  
 
 
SQUAMOUS CELL CARCINOMA 
                               Squamous cell carcinoma of the lid account for 5% of 
all lid malignancies. It presents with various degrees of malignancies. 
• Intraepidermal SCC –less invasive, present as telangiectatic flat 
area 
• Bowens disease- Erythematous, demarcated, scaly patch, growing 
slowly in a centrifugal manner. 
• Squamous cell carcinoma- Raised tumor with eroded centre or can 
present as a flat indurated lesion 
                     Histologically the epithelium shows complete 
disorganization with numerous atypical cells. Invasion of the 
dermis is the hall mark of invasive SCC. Metastasis rate is low 
and occurs via lymphatics. 
                      Treatment is surgery with microscopic evaluation, 
and this gives the best results. Radiotherapy is the next 
treatment of choice. Cryotherapy can be given. 
 
  
SEBACEOUS GLAND CARCINOMA 
                 It accounts for 1.5-5% of all lid malignancies. Although the 
tumor is referred to as mebomian gland carcinoma the general term is 
preferable since this tumor may aris from glands of Zeis, sebaceous 
glands of caruncle and eye brow. The upper lid is involved more 
commonly. 
     In over 60% of cases, the tumor presents as a pseudochalazion, 
chronic blepharitis, meibomitis, superior limbic keratoconjunctivis. The 
tumor can present as a focal mass, multicentric tumor involving both the 
lids or a diffuse lesion with pagetoid spread to tarsal and bulbar 
conjunctiva. 
     Most commonly the lesion spreads into the orbits, lymphatic 
spread to the regional lymphnodes, less commonly other organs including 
lungs, brain, liver, bones are involved. 
     Histologically the normal glandular cells are replaced by 
neoplastic cells arranged in lobular, papillary, cords, diffusely scattered 
and combined forms. Oil red O stain for fat is useful to differentiate 
sebaceous carcinoma from other malignancies. 
 
      Poor prognostic factors include multicentric origin, lymphatic 
or orbital spread, tumor diameter more than 10mm, poorly differentiated 
tumors. 
  Treatment is by complete excision with 5-6mm of normal tissue 
on all sides, with frozen section evaluation. Radiotherapy is considered 
less effective, 55 Gy gives fairly good results. 
MALIGNANT MELANOMA 
• It accounts for  1% of eyelid tumors. There are four types of 
cutaneous melanomas . 
• Lentigo maligna(Hutchinsons freckle)- radial growth phase 
existing for many years leading to a vertical growth phase with 
elevated lesion at this point. 
• Superficial spreading melanoma – appears as nodule or plaque 
with variable pigmentation 
• Nodular melanoma – has only vertical growth phase with early 
involvement of the dermis and has the worst prognosis 
• Acro- lentiginous - rare in eyelids 
           Treatment includes complete preoperative metastatic work-up in 
tumors >1.5mm in thickness. Wide surgical excision >than 5mm margin 
 with frozen section evaluation. Regional lymphnode dissection should be 
done in patients with evidence of microscopic vascular, lymphatic 
involvement. 
LYMPHOMA 
 Polymorphic B cell lymphoma occurring in 
immunodeficient patient presents with ulceration of lid skin. Mycosis 
fungoides , a T cell lymphoma can affect the skin. 
 Surgical excision does not give good results, usually followed by 
recurrences. Radiotherapy is the treatment of choice. 
KAPOSI SARCOMA 
         It is a common manifestation of AIDS. The tumor may be nodular 
and confined to the skin, or florid with locally destructive skin lesion. 
The tumor is often violaceous in colour and the conjunctival involvement 
may simulate inflammation. Treatment is with low dose radiotherapy. 
 
 
 
 
METASTATIC EYELID CARCINOMA 
              Metastatic tumors to the lids are very rare. Breast and lung 
carcinomas account for 80% of lesions, rarely stomach, kidney, parotid 
contribute to metastasis. These lesions present as painless nodules or 
ulcerative lesions. The survival after the appearance of lid metastasis is 
less than 1 year. 
RARE LID MALIGNANCIES  
                           Merkel cell tumor typically involving the upper lid are 
low grade neoplasms derived from neural crest cells of the skin. They 
present as painless, violaceous tumors with telangiectasia. 
                            Mucinous sweat gland adenocarcinoma and malignant 
syringoma are rare tumors arising from eccrine or apocrine sweat 
glands. 
      
 
                
 
 
                 MANAGEMENT OF LID TUMORS 
            The management of all lid tumors depends on correct 
histological diagnosis, assessment of tumor margins and the extent of 
systemic tumor spread. 
 At the initial evaluation of all lid tumor patients a complete 
systemic examination  including weight, lymphnodes, respiratory and  
abdominal examination. A complete blood picture, serum liver function 
tests, chest X- ray, CT scan orbit(in suspected orbital invasion) are 
obtained. 
                      Diagnosis of lid tumors is based on history, clinical 
features, examination, investigations and  biopsy. Excisional biopsy is 
preferable for small lesions and involves excising the whole lesion. 
Incisional biopsy involves taking a piece of the lesion with an adjacent 
edge of normal tissue for comparison. 
NON SURGICAL TREATMENT  
CRYOTHERAPY 
                      Epithelial tumors-basal and squamous cell carcinoma, 
benign lesions- keratosis, papillomas can be treated with direct liquid 
nitrogen spray or by an appilacator tip that has circulating liquid nitrogen. 
Using a double or triple freeze –thaw technique tumor must be frozen to -
30°c. 
                      The complications are lid notching, depigmentation, loss of  
lashes. The main disadvantage is the lack of histological proof of 
clearance.  
RADIOTHERAPY  
 Radiotherapy is as effective as surgery in small tumors. It is 
useful where surgery is contraindicated. SCC, BCC, lymphoma, kaposis 
sarcoma are radiosensitive.  
                     Methods used are contact therapy, external beam radiation 
and brachytherapy. The two most commonly used external beams are 
orthovoltage photons and megavoltage electrons. Most of the lid tumors 
are treated with orthovoltage systems. 
                     For BCC 300rads daily fractions of orthovoltage photons to 
a total dose of 45-50Gy is used. A normal lid margin of 1cm is included 
in the treatment field. Recurrence rate is 5-10%.  
                      Radiotherapy can be highly effective in the management of 
capillary hemangiomas. Orhtovoltage therapy 150-250 rad range is given 
in a single dose. Other indications include papillomas, recurrent tumor 
after surgical removal. Complications include lid atrophy, skin necrosis, 
cictrax formation, keratitis, lacrimal drainage obstruction, radiation 
induced malignancy.  
 CORTICOSTEROID THERAPY  
                        Kushner’s regimen- intralesional therapy is used in the 
treatment of capillary hemangiomas. Injections of 40mg of triamcinolone 
and 6mg preparation of  betamethasone acetate and betamethasone 
phosphate are used. Most tumors require 2 or more injections. Involution 
of tumor begins several days after injection and becomes considerable in 
2-4 weeks time. Complications include lid necrosis, lid atrophy, 
depigmentation and systemic adrenal axis suppression. 
                         Systemic prednisolone and topical therapy with 
clobetasol propionate have also been used for treating infantile 
hemangiomas. 
LASER THERAPY 
                           Laser therapy has been used for treating capillary 
hemangioma, BCC, Papilloma, actinic keratosis. Co2 laser vaporizes 
tissues by heating intracellular water. It also seals lymphatics and could 
prevent lymphatic spread of tumor. Argon laser, NdYAG laser and dye 
laser have been used for capillary hemangiomas. 
INTERFERONS 
  Intralesional injections of human recombinant ά- interferon 
has been used to treat capillary hemangioma and BCC. The mechanism 
 of action is believed to be inhibition of endothelial and fibroblast 
proliferation, as well as prostaglandin synthesis. Complications include 
retinal vasculopathy, fatigue, vomiting, leukopaenia and neurotoxicity. 
CHEMOTHERAPY 
                        Topical 5-Fluorouracil has been reported to eliminate SCC 
insitu. Its use in eye lid tumor is limited by the side effects of ocular 
irritation. Cisplatinum, doxorubicin and bleomycin has been used in the 
treatment of non resectable BCC. 
SURGICAL TREATMENT OF LID TUMORS 
                        Two techniques are currently accepted for surgical 
treatment of tumors. 
• Mohs fresh tissue technique 
• Frozen section control using microscopic evaluation of margins 
MOHS MICROGRAPHIC TECHNIQUE 
                          This technique was described by Fredrick Mohs in 1930. 
Originally zinc chloride was used to fix cancerous tissue and then the 
tumor is excised in layers and examined microscopically to see the extent 
of the tumor. Zinc chloride causes ocular irritation and is not is used in 
lid tumors. 
                             Fresh tissue technique –Mohs chemosurgery. This 
technique includes, 
• Injection of local anesthetic  
• Tumor is excised by thin layers 
• The sections are stained and numbered  
• Tumor can be followed to its depth and extentions beyond the 
clinically apparent tumor can be removed 
                    Surgeons trained in Mohs chemosurgery removes the 
tumor and either allows the area to heal by granulation or refers the 
patient to reconstructive surgeon. 
ADVANTAGES 
• The use of two different teams to separately resect and reconstruct 
the eyelid avoids inadequate tumor margin resection. 
• 95% cure rate has been achieved 
• Low incidence of tumor recurrences 
 
 
DISADVANTAGES 
 • The tumor must be interpretable by light microscopy and by frozen 
sections 
• Tumor must grow in a continuous manner without skip areas 
• The need for a trained dermatopatholigst . 
FROZEN SECTION CONTROL 
                          In contrast to most techniques attempt is made to remove 
entire tumor at once. Incision is made to include tumor and 2-3mm of 
normal appearing tissue around tumor. The currently acceptable 
technique is to take thin slices of the three borders of the excised tumor 
and examine these sections. This will evaluate all of the specimen 
margins and is similar to most technique for finding tumor extension no 
matter in which direction it may be headed. 
                          This approach requires the pathologist to work closely 
with the surgeon. And if there is extension to any of the tumor margin, 
further  dissection is done only in that area. 
 
 
GENERAL PRINCIPLES OF LID RECONSTRUCTION 
 The central focus of eyelid reconstruction is the 
reconstitution of a dynamic protective covering for the cornea. The key to 
 a successful eyelid reconstruction is to properly assess the size of the 
defect and to separate the complex defect into component parts or 
subunits. 
              Since eyelid tissues retract in the presence of  discontinuity 
residual lid margins has to be distracted under normal tension in order to 
assess the true size of the defect. In surgical planning one must assess the 
amount, location of inner and outer lamellar defects. 
ANTERIOR LAMELLAR DEFECTS  
1. Direct skin closure-in the pretarsal area defects are sutured 
vertically 
2. Laisser-faire indicated for medial canthal defects. The defect is 
allowed to heal by granulation in 1-3 weeks time 
3. Skin flaps-in oculoplastic surgery flaps are classified as  
• Sliding flap is one in which skin relaxation is obtained by 
undermining 
• Advancement flap-Tenzel, U, H, O-T, O-Z –in this relaxing 
incisions are used on either side of the flap to obtain greater 
mobilization 
 • Rotation flap—rhombic flap, involves rotation of the flap 
around an axis with closure of the remaining defect directly 
or with the skin graft 
• Transposition flaps- skin muscle flap from upper eyelid to 
lower eyelid, forehead to lower eyelid, the nasolabial flap. 
  Flaps have numerous advantages over skin graft. A flap 
brings its own blood supply and causes minimal contracture compared to 
a skin graft. There is increased resistance to infection, and a better colour 
and texture match is obtained with skin flaps. 
4. Skin grafts-Full thickness grafts are preferably taken from 
preseptal upper lid skin, post auricular, supraclavicular regions. 
POSTERIOR LAMELLAR DEFECTS 
 Posterior lamellar flap - from upper lid tarsal plate for lower 
lid defect. Posterior lamellar graft - mucosa from upper lip, lower lip, 
cheek hard palate. 
FULLTHICKNESS DEFECTS  
  Combination of flap and graft are used to reconstruct both 
anterior and posterior lamella. Depending on the horizontal extent of 
defect  
<25%- direct closure 
 <33%- direct closure with cantholysis 
<50%- lateral rotation flap 
>50%- pedicle flap, Kollner for lower eyelid, Cutler- Beard for upper 
eyelid 
MARGIN SHAVE EXCISION 
  Elevated benign lesions of the lid margins that do not have 
deep extensions and not involving the cilia can be shaved off  flush to the 
level of the desired lid margin. The raw area is then lightly treated with 
electrocautery to achieve hemostasis. Notching of the lid does not usually 
occur. 
TRANSMARGINAL PENTAGONAL WEDGE RESECTION 
                     Lesions involving the lid margin or the full thickness of the 
eyelid can be excised by a pentagonal wedge resection . Pentagonal 
excision of the tumor is done to eliminate wrinkling of skin when closure 
is performed. 
RECONSTRUCTION OF THE UPPER EYELID DEFECTS 
1. SMALL DEFECTS-DIRECT CLOSURE +/- CANTHOLYSIS  
              Up to 25% full thickness defects can be closed primarily in 
younger patients. Increased laxity in older patients allows direct closure 
in up to 40% defects with the use of lateral cantholysis. The most 
 important part of direct closure is approximation of tarsal plate with three 
absorbable sutures and maintaining continuity of lash line with two 
sutures in the lid margins.  
1. MEDIUM SIZED DEFECTS-TENZEL LATERAL 
SEMICIRCULAR ADVANCEMENT FLAP. 
  Up to 15mm defects can be repaired by Tenzel flap. After 
tumor excision and a lateral canthotomy an inferior arching line is 
drawn beginning at the lateral canthus and extending laterally and 
inferiorly for 20-30mm up to the lateral extension of the brow, 
confined to the periorbital skin. This flap is mobilized and brought 
nasally and sutured to the tarsal remnants of the lateral lid. The 
conjunctiva is mobilized to the posterior surface of the new lateral 
upperlid. The lateral canthus is reformed by suturing the flap tissue to 
the periosteum. 
2. MEDIUM SIZE DEFECTS WITH RESIDUAL TARSUS 
AFTER TUMOR EXCISION 
  MODIFIED TARSOCONJUNTIVAL FLAP  is 
fashioned from the everted upperlid near the wound edge equal to 
the dimension of the defect. This flap is sutured to the remaining 
 tarsus of the upper lid. Skin is closed with advancement flap from 
surrounding skin. 
 
3. LARGE DEFECTS –CUTLER- BEARD BRIDGE FLAP 
  Defects more than 15mm size can be reconstructed by this 
technique. This procedure borrows skin, muscle, conjunctiva from the 
lower eyelid which is transposed to the upperlid defect. The incision is 
made 5mm below the lowerlid margin, length of incision should match 
horizontal dimension of the defect. Vertical incisions are made from the 
ends of horizontal incision. This flap is mobilized under the bridge of the 
lower lid and suture it in layers into the defect. Leave the flap to stretch 
for 3 months. In the second stage the bridge flap is divided, leaving more 
conjunctiva than skin. Conjunctiva is used to reform new lid margin. 
 In many cases of massive tissue loss of  the upper eyelid, 
when the tissue cannot be borrowed from lower lid or adjacent areas, 
flaps are brought in from remote areas. Median forehead flap- 
supraorbital and supratrochlear arteries provide excellent blood supply to 
the median fore head allowing long flaps to be developed. Temporal 
forehead flap- Fricke flap, this is a thick flap requiring a lining with 
conjunctiva or buccal mucosa. 
  
 
 
RECONSTRUCTION OF THE LOWER EYELID  
1.SMALL  DEFECTS- PRIMARY CLOSURE +/- CANTHOTOMY 
  Up to 5-10mm defects in the centre can be closed by 
primary closure by suturing the tarsal plates together. For defects in the 
lateral or medial ends of  the lid, the tarsus is sutured to the medial or 
lateral canthal tendon. 
2.MEDIUM LOWER LID DEFECTS- TENZEL SEMICIRCULAR 
ADVANCEMENT FLAP 
  This advancement flap is most useful for moderate size 
defects in the lateral portion of the lower lid. REVERSE CUTLER-
BEARD procedure can be used for central defects but has the 
disadvantage of obscuring the visual axis for 6-8 weeks.  
  MODIFIED HUGHES PROCEDURE- this procedure 
consists of a tarso-conjunctival flap brought from the upper lid and using 
a skin graft for the anterior lamella 
3.LARGE DEFECTS-MUSTARDE’S ROTATIONAL CHEEK 
FLAP 
   In this procedure a large temporal cheek flap is mobilized by 
extensive undermining and used to close the defect in the lower eyelid, 
the defect is usually in the shape of an isosceles triangle. Cheek skin is 
not a good replacement as it often contains facial hair. A graft of 
chondromucosal cartilage, conchal cartilage or fascia lata strip lined with 
buccal mucosa is used to form the posterior lamella. 
4.DEFECTS IN THE MEDIAL CANTHAL REGION 
 It is an aesthetic, functionally important area. A V-Y or 
GLABELLAR flap is used. An inverted V incision is made in the 
midline of the brow, the flap is undermined, leaving a pedicle at the 
bridge of the nose. Close the brow defect to form the stem of the inverted 
Y, this advances the flap and it is rotated and sutured to the defect. 
  MYOCUTANEOUS ISLAND FLAP- A triangle of skin and 
muscle inferior to the defect is brought on to the defect as a skin muscle 
flap. The acute angle of the medial canthus can be reconstructed by 
passing a 0.3mm titanium wire from the tip of the tarsal plate of upper,  
lower lid and fixed onto the nasal bone.  
 
 
 
  
 
 
EXENTERATION 
                   This is a destructive procedure which involves removal of 
the globe and all the contents of  the orbit along with the periosteum. 
It is indicated when there is extensive tumor involvement of the ocular 
adnexae. Following surgery granulation tissue is allowed to proliferate 
and cover the orbital walls. The patient is normally provided with a 
spectacle mounted prosthesis to overcome the cosmetic defect.                               
 
 
 
       
                               
 
 
  
  
                    
  
 
                            AIM OF THE STUDY 
            The aim of this study is to analyze the incidence, pattern of 
presentation, clinical correlation with histopathological report, treatment 
response in all lid tumors presenting to a tertiary care hospital. 
 
 
 
 
 
 
 
 
                   MATERIALS AND METHODS 
                         This is a prospective study of patients with various lid 
tumors who presented to the oculoplasty Department of  Regional 
Institute  of  Ophthalmology and Govt. Ophthalmic hospital Chennai. 
 Forty patients with lid tumors who have undergone various modalities of 
treatment have been included in the study.  
                           A standard clinical proforma was filled in all cases with 
salient features including history, age, sex, presentation, duration of 
growth, laterality, prevous surgical treatment, h/o recurrences, etc. 
Patients were subjected to basic investigations. If there was clinical 
evidence or suspicion of metastasis, CT scan, renal and liver function 
tests were performed.  
                            Each tumor was studied histopathologically with the 
help of excision/ incision biopsy. All operable tumors were treated in our 
hospital and the lid defect was reconstructed using appropriate 
procedures. Patients were discharged after wound healing and were 
followed up on outpatient  basis at 1 month, 3 months and 6 months 
interval. During follow up patients were examined in detail to detect 
recurrences or metastasis. Few patients were lost for follow up. 
 
 
 
 
 INCLUSION CRITERIA – Patients with various benign and malignant 
tumors who presented to the o.p.d were included in the study.  
EXCLUSION CRITERIA - Patients with chalazion, a chronic 
granulomatous inflammation have not been included in the study.  
Patients with congenital or traumatic lid defects have not been included 
in the study. 
 
 
 
 
 
 
 
 
 
                    OBSERVATIONS AND ANALYSIS 
1. Study group consisted of 40 patients 
   In this group 25 patients with benign lid tumors and 
15patients with malignant lid tumors were studied. 
2. Age distribution 
      Age Group           Benign            Malignant 
          < 10 yrs          5  (21.74%)               - 
         10-29 yrs           6 (26.09%)               1(5.88%) 
         30-45yrs           7 (30.43%)               3 (17.65%) 
        46-60 yrs            4 (17.40%) 4 (23.53%) 
 >60 yrs            1 (4.3%)                     9 (52.94%) 
 
                            In this study, malignant tumors were commonly in 
the age group between 60-85 years and benign tumors were common 
in the age group of 30-45 years. 
                            The  AFIP study has found malignant tumors to be 
common between sixth and ninth decades of  life. Similar to this 
majority of malignant tumors were common in the older age group.  
Age distribution of individual tumors 
Tumor Range Average age 
Basal cell carcinoma 67-68 years 67.5 
 Meibomian carcinoma  42-84 years 62.2 
Squamous cell carcinoma 55-68 years 61.1 
 
                          According to Carol L.Shields, meibomian 
carcinomais common between fifth to ninth decades and basal cell 
carcinoma between 50-80 years. In our study, we found younger age 
group patients presenting with meibomian carcinoma. 
3. Sex distribution 
Tumor  Male Female 
Benign 12(52.17%) 11(47.83%) 
Malignant 6 (35.29%) 11(64.71%) 
 
 
Sex distribution in malignant tumors 
 
Tumor  Male  Female 
Meibomian carcinoma 3(37.5%) 5(62.5%) 
Squamous cell carcinoma 2(50%) 2(50%) 
Basal cell carcinoma 1(50%) 1(50%) 
 
                 Incidence of meibomian carcinoma was more among 
female patients. This correlates with the study of Carol. L Shields who 
found slight female preponderance on meibomian carcinoma 
 
 4. Lid involved 
 Benign  Malignant 
Upper lid  16(69.57%) 10(58.82%) 
Lower lid 7(30.43%) 5(29.41%) 
Both lids              - 2(11.76%) 
 
                      In this study, benign and malignant tumors were found 
to occur more commonly in the upper lid 
 
 
5. Specific sites of involvement of malignant tumors 
Tumor UL LL BL             Canthus 
Medial           
Lateral 
Meibomian 
carcinoma 
5(62.5%) 2(25%) 1(12.5%)          1      3 
Squamous 
carcinoma 
4(100%)     -        -            -       1 
Basal cell 
carcinoma 
     - 2(100%)       -          -       - 
NHL-B cell     1       -        -          1       - 
 Malignant 
melanoma 
      -       1        -           -       - 
Secondaries       -       -         1           1       - 
• Ni et al 1982(70.12%), Doxanas & Green 1984(48.71%) and Wolf 
et al 1984(58.53%) have reported sebaceous carcinoma commonly 
on the upper eyelid. Similar to this majority of sebaceous 
carcinomas (62.5%) in this study, were found to occur on the upper 
eyelid. 
• Aurora Al and Blodi FC found Basal cell carcinoma to be more 
common in the upper eyelid and the next most common site was 
the medial canthal area. In this study, both the cases of basal cell 
carcinoma were found in the lower lid. 
• In this study squamous cell carcinoma was found to occur more 
commonly in the upper lid similar to other studies. 
6. Size of the tumor 
               Size of the tumor at presentation ranged from 5-25mm  
7. Involvement of lid margin 
                 This was found in 10(43.48%) patients with benign 
tumors and the lid margin was involved in 9(52.94%) patients with 
malignant tumors   
 8. Predisposing factors 
                   Trauma has been described most often in literature as a 
predisposing factor for squamous and basal cell carcinoma. In this 
study 25% of malignant tumors & 20% of benign tumors had h/o 
trauma. One patient with NHL- B cell lymphoma was HIV 
positive. Majority of the patients were from the rural areas with 
history of exposure to sun for long periods. Few patients gave a 
history of chronic blepharitis. Association with Diabetes mellitus  -   
Fifteen percentage of patients with benign tumors and 25.6% of 
patients with malignant tumors were diagnosed to have diabetes 
mellitus. 
 
 
 
9.  Incidence of benign tumors  
Hemangioma                  -                    6 (26.08%) 
Neurofibroma                 -                    4 (17.4%) 
Intradermal nevus           -                    3 (13.04%) 
Dermoid                         -                      1 (4.35%) 
Molluscum                     -                      1 (4.35%) 
 Pyogenic granuloma       -                     1 (4.35%) 
Trichoepithelioma          -                      1 (4.35%) 
Papilloma                        -                      2 (8.70%) 
Sebaceous cyst                -                      4 (17.40%) 
                        Hemangomas constituted the most common of the 
benign tumors, corresponding with the observation of Aurora Al 
Blodi FC & Char et al .   
          Malignant 
          Sebaceous carcinoma            -                8(47.06%) 
          Squamous cell carcinoma      -                4(23.53%) 
          Basal cell carcinoma               -              2(11.76%) 
          Malignant melanoma              -               1(5.9%) 
          NHL-B cell                             -                1(5.9%) 
          Secondary tumor                    -                 1(5.9%) 
                                  Aurora, Blodi et al have found BCC to be the 
commonest malignancy in the periocular region, constituting about 80-
90% of all malignancies. The second most common tumor is Squamous 
cell carcinoma, the incidence has been variable, Mortada 1967 (30.21%), 
Anderson 1982 (4.7%).  
                                 The third most common eyelid malignancy has 
traditionally been sebaceous carcinoma. Doxar and Green 1984 (4.7%), 
Ni and Shangha et al (32.7%). In this study, however we found an 
increased incidence of sebaceous carcinoma. 
                                  This results correlates with the similar study 
conducted at our institute in which there was an increased incidence of 
sebaceous carcinoma. This could be attributed to the high humidity and 
sweat factor in the coastal areas. 
                                   The next most common malignancy is squamous 
cell carcinoma followed by  BCC. A rare case of malignant melanoma, 
NHL- Large B cell lymphoma, metastatic tumor has been reported in this 
study.  
Clinical presentation of malignant tumors 
Presentation Sebaceous 
ca 
      BCC      SCC Percentage 
Nodule            3          -        2     35.71% 
Ulcerative 
growth 
          5          2        2    64.29% 
 
                                The most common presentation of malignant tumors 
was in the form of an ulcerative growth. Nodular growth pattern was seen 
in 35.71% of patients.  
• Majority of sebaceous carcinoma presented in ulcerative 
form(62.5%) 
• The two cases of BCC presented in the form of ulcer with elevated 
margins 
• SCC showed both nodular and ulcerative forms 
10. Tumor infiltration 
           Tumor           Globe           orbit 
Sebaceous carcinoma           1 (12.5%)        1 (12.5%) 
BCC                -                - 
SCC                -                - 
 
                            Tumor infiltration of the globe or orbit is most 
common in cases of sebaceous carcinoma, incidence being 6-17% 
in studies by Boniuk, Zimmerman et al and Ginberg et al.  
                          In our study extension of tumor to globe and orbit 
was more common in sebaceous carcinoma. 
11. Metastasis to regional lymph nodes 
                  It was found in 6 patients with malignant tumors on 
presentation 
 Sebaceous carcinoma              -                     2(25%) 
 Squamous cell carcinoma       -                      1(25%) 
 BCC                                        -                      1(50%) 
 NHL- B cell lymphoma, secondary lid tumors presented with 
metastasis to regional lymph nodes. According to the AFIP series, 
the incidence of lymph node extension in sebaceous carcinoma is 
28%. This correlates with our study reports. 
12. Correlation with histopathological diagnosis 
                            HPE correlation was obtained in 85% of benign 
tumors and 80% of malignant tumors. 
13. Management  
   Benign tumors 
• In most of the tumors up to 7mm in size, excision of the 
tumor was done and the specimen was sent for HPE. There 
was no structural and functional abnormality of lids 
postoperatively. 
• In patients with pyogenic granuloma, papilloma, molluscum 
up to 5mm in size marginal shave excision was done 
 • In cases with neurofibromas surgical debulking of the tumor 
was done 
• In three cases of hemangioma excision was done and two 
cases of hemangiomas were treated with systemic steroids. 
The two cases treated with oral dexacortil, showed 
regression on follow up. 
• In a patient with junctional nevus, excision of the lesion with 
primary closure of the defect in three layers was done. 
 
 
 
 
 
 
 
 
Malignant tumors 
Tumors Pri. 
Cl 
With 
cantholysis
               Flaps 
TLAF   MF    GF      CuB 
RT Exentr 
Meib ca     1       1   1   1    2    1    -       1 
BCC     -       -   -   1    1   -    -      - 
SCC     1       2   1   -    -   -    1      - 
NHL Bcell     -       -   -   -    -   -    1      - 
Secondaries     -       -   -   -    -   -   -      1 
 
 • In one case with sebaceous carcinoma and in one case of SCC 
involving up to one fourth of the lid, tumor was excised by a 
pentagonal incision and the resulting defect was closed by direct 
approximation in three layers i.e. conjunctiva and trarsus, 
orbicualris muscle and skin. 
• In three cases where difficulty was experienced with direct closure 
a lateral cantholysis was performed in order to relax the the rest of 
the lid and to allow a good closure of the defect.  
• One case of sebaceous carcinoma involving the lower lid and 
medial canthal area was repaired after excision, with the help of 
glabellar rotation flap and Mustarde’s advancement flap. 
• One case of sebaceous carcinoma, one case of SCC, the tumor 
wase excised and the defect repaired with Tenzel lateral 
advancement flap. 
• One case of meibomian carcinoma, one case of BCC involving the 
medial canthus the tumor was excised and the defect repaired with 
Glabellar flap. 
• In one case of sebaceous carcinoma, after tumor excision Cutler 
Beard technique was performed to close the defect in the upper lid. 
 The bridge was released after 9 weeks and secondary 
reconstruction was done. 
• A rare case of NHL large B cell lymphoma was referred to Barnard 
institute for radiotherapy. 
•  A rare case of malignant melanoma was treated with excision, the 
patient developed secondaries and was referred to Department of 
oncology. 
• One case of recurrent meibomian carcinoma and one case of 
secondary tumor infiltrating the eyelid and the orbit under went 
orbital exentration 
14. Surgical complications 
•  Mild Ptosis occurred in one case of neurofibroma after 
debulking  
• Lid notching was noted in a case of sebaceous carcinoma 
following  primary closure 
• Large scar line was noted in a case which underwent 
Mustarde’s cheek rotation flap 
• Poor lid closure was found in a case of sebaceous carcinoma 
for which Tenzel lateral advancement flap was performed  
15. Recurrence 
             Recurrence was reported in one patient. The patient was 
diagnosed to have sebaceous carcinoma during the initial 
presentation 
 Incidence of recurrence in all tumors            -      5.89% 
Incidence in sebaceous carcinoma                 -      12.5% 
                       Epstein GA et al and Harvey JT et al have reported 
recurrence in patients with sebaceous carcinoma to be between 9-
36%. In our study the incidence of recurrence is 12.5%. 
16. Mortality  
                Among 17 patients with malignant tumors, one patient 
with sebaceous carcinoma expired. One patient with malignant 
melanoma had systemic metastasis during initial presentation. 
                The AFIP study and Rao, Mc Lean et al have quoted 15-
30% tumor related mortality for sebaceous carcinoma. In our study 
the mortality is 12.5% for sebaceous carcinoma. 
                Birge et al – 20.5%, Aurora et al – 40%, have reported 
mortality figures for SCC. Mortality for BCC is between 2-11%. In 
our study no deaths have occurred in patients with SCC, BCC. 
       
                          
 SUMMARY 
A total of 40 patients (23 benign and 17 malignant) with lid tumors were 
studied.  Benign tumours were common between 2nd –4th decade and 
malignant tumors in 6th decade and above. Two patients of younger age 
group also presented with BCC and meibomian carcinoma. In contrast to 
other studies we found increased incidence of malignancies occurring in 
females esp. Meibomian gland carcinoma in our study. 
 
 There was a predilection for upper lid in 62.5% of meibomian 
carcinomas and 100% of squamous cell carcinomas. BCC involved 
mainly the lower lid and canthal areas. History of trauma was there in 
20% of benign tumors and 20% of malignant tumors Hemangiomas rank 
first in commonly occuring benign tumors and gland carcinoma in the 
malignant group. Majority of meibomian gland carcinomas presented in 
the form of nodules whereas BCCs and squamous cell carcinomas 
predominantly showed ulceration. Tumor infiltration to adjacent 
 structures was more common in BCC’s and squamous cell carcinomas. 
Correlation with HPE diagnosis was obtained in 80% of malignant 
tumors. 
 Excision of the tumor was the common modality used for 
management of benign tumors. In the malignant group, tumor excision 
with primary closure was done in 26.6% of cases, cantholysis was 
combined in another 26.6%  of cases. Various types of rotation flaps / lid 
sharing techniques were used in 46.6% of cases. 26.6% of cases were 
referred for radiotherapy. The incidence of recurrence was 12.5% in 
malignant tumors. Recurrence was more commonly reported in 
meibomian carcinomas. Both patients who expired during follow up had 
systemic metastasis at presentation. The mortality rate is 12.5% . 
 CONCLUSION 
1. Benign tumors commonly affected patients in age group of 30-45 
years and malignant tumors >60 years of age. 
2. The incidence of malignant tumors was more in females. 
3. In contrast to western studies meibomian gland carcinoma 
appeared to be the most common type in this study and upper lid 
was the most common site of involvement. 
4. Meibomian carcinoma can be considered as the first diagnosis in 
cases presenting with nodulo ulcerative form and BCC or 
squamous cell carcinoma in cases presenting  in the form of ulcers. 
5. Histopathological diagnosis differed from the clinical diagnosis in 
20% of malignant tumors and in 15%  of benign tumors. So, all 
excised eyelid lesions should be submitted for histopathological 
examination. 
6. All the recurrent cases were diagnosed as meibomian carcinomas 
and recurrence rate of 12.5% correlates with other studies. 
7. Lid malignancies showed a predilection for lid margin where 
excision necessitates plastic repair. 
8. Malignant tumors when detected early, were found to respond well 
to primary excision of tumor with appropriate lid repair 
procedures. 
9. Adequate surgical clearance (atleast 5mm of normal tissue around 
the tumor) should be obtained to prevent recurrence. 
10. The central focus of eyelid reconstruction is the reconstitution of a 
dynamic protective covering for the cornea. The key to successful 
reconstruction is to properly assess the size of the defect and to 
separate the complex defect into component subunits.  
 11. In surgical planning one must assess the amount, location of the 
defect and utilize various techniques  to bring about a good 
cosmetic correction and    functional  
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 MASTER CHART 
 
SL 
N
o 
Name Age 
/Sex 
Present
ation 
Lid 
Involved 
Involvem
ent of 
can thus 
margin 
Consiste
ncy 
Skin 
Around 
the 
Tumor 
Associated 
Iid 
anomalies 
Infiltrati
on of 
orbit 
Lymph 
nodes 
Clinical 
impressi
on 
1. Valliammal 68/F Ul, Gr RLL MC H DC Ect, ma Con - SCC 
2. Mahalakshmi 45/F Sw LUL - S - Pt - - Hem 
3. Arumugam  25/M Gr LUL MC LC S DC Pt Ma - - NF 
4. Immanuel 7/M Sw LUL - S DC Pt - - Hem 
5. Muthu 67/M No LUL - F DC Pt. Ma - - MBC 
6. Lakshmi 50/F Sw RUL - S - - - - SC 
7. Bharathi 2m / F Sw LUL LC S DC Pt - - Hem 
8. Mariammal  40/ F Sw RLL - S - - - - Moll 
9. Manikandan 17/M Sw RUL LC S DC Pt - - NF 
10. Sivakumar 30/M Sw LLL - S - - - SM PG 
11. Fathima Beevi 67/F Ul RLL - F DC Ma - PA BCC 
12. Poongodi 39/F Sw LUL - S - - - - SC  
13. Prema 30/F Sw RUL - S - Pt - - SC 
14. Kattan 42/M Gr,ul LLL LC H DC Ma, Ect - - MBC 
15. Sampath kumar 50/M Gr, ul RUL LC H DC Ma, Ect - PA SCC 
16. Murugan 3m/M Sw LUL - S DC Pt - - Hem 
EXCISION WITH PRIMARY CLOSURE 
 17. Venkatesan 30 /M Gr, Ul LUL MC F DC Pt, Ma - SM Lympho
ma 
18. Vinodhini 1/F Sw RUL LC S DC Pt - - Hem 
19. Amudhavalli 70/F Gr LLL MC F - Ma - - Nev 
20. Muthammal 45/F Gr, Ul LUL - H DC Pt - - MBC 
21. Kavitha 20/F Sw RUL - S DC Pt - - NF 
22. Sathish  25/F Sw RUL - S - - - - Der 
23. Meenakshi Sundaram 68/M Gr, Ul LUL LC H DC Ect - PA MBC 
24. Parvathi 50/F Gr  LLL - F DC - - - Papilloma
25. Pencilliah 60/M Gr RLL LC F DC - - - Nev 
26 Sivagami 65/F No LUL - H - - - - SCC 
27. Subramani 68/F Gr, Ul RLL - H DC Ect, Ma - - BCC 
28. Venkatammal 60/F No RULL - F - Pt - - MBC 
29. Titus 5/M Sw RUL LC S DC Pt - - NF 
30. Vasantha 20/F Sw LUL - F - - - - Der 
31. Tulukanama 84/F Gr, Ul LUL, LLL LC H DC Ect, Ma + PA MBC 
32. Senthil Vel 50/M Gr LLL  - S - Ect,  - - Papilloma
33. Mohan  43/M Gr RLL - F DC - - - Papilloma
34. Penicillama 62/F No RUL - F - - - - MBC 
35. Subbamma 60/F No LUL - H DC Pt - - SCC 
36. Sumathi 40/F SW LUL - S - Pt - - Hem 
37. Mahalakshmi 18/F Gr LUL, LLL MC, LC H DC Pt + SM, PA Sec 
38. Munusamy 65/M Gr, Ul LUL - H DC Pt, MA - - SCC  
39. Balamurugan 15/M Sw RUL - S DC Pt - - Hem, 
Nevus 
40. Pattammal 60/F Gr RLL - F - - - - Der  
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 PART  I 
 
                             PROFORMA 
Name     :                                                                                     DOA : 
Age/Sex  :                                                                                   DOS  : 
Hos. No    :                                                                                  DOD : 
Occupation : 
HISTORY  
Onset 
Progress 
Pain 
Discharge / Bleeding 
Similar lesions elsewhere 
Trauma 
Defective vision 
Treatment  - Medical / Radiotherapy / Surgical 
- H/O. Treatment for ENT symptoms 
 
PERSONAL HISTORY 
Diabetes / Hypertension 
Loss of appetite / weight 
Bowel / Bladder habits 
 
ON EXAMINATION 
Visual axis 
Extra ocular movements 
Bony orbit / proptosis 
 
LIDS 
Tumor / ulcer 
Upper lid / lower lid 
Medial / lateral canthus 
Margin involvement 
 Size, shape, measurement 
Base / floor of ulcer 
Discharge /  blood  
Tenderness / consistency  
Skin around tumor 
Mechanical ptosis / ectropion  
Madarosis / trichiasis 
Adherence to bone / globe 
 
CONJUNCTIVA  
Extension of tumor 
Bulbar / palpebral 
Congestion  / discharge 
 
CORNEA 
AC 
IRIS  
PUPIL  
LENS  
FUNDUS 
VISION 
LACRIMAL PASSAGES 
IOP 
LYMPHNODES 
Size, consistency, mobility, tenderness 
 
GENERAL EXAMINATION 
CVS/ RS/ CNS/ ABDOMEN 
 
CLINICAL IMPRESSION 
 
INVESTIGATIONS 
Blood  
Urine 
Orbital X-ray/ B-scan 
CT-scan 
 
HISTOPATHOLOGY 
Gross 
Microscopy 
 Impression 
 
TREATMENT 
Medical  
Surgical- Excision 
                Excision/ reconstructive procedure 
                Exenteration 
Adjuvant therapy 
Radiotherapy/ Chemotherapy 
 
FOLLOW UP 
 
RECURRENCE 
 
METASTASIS 
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LID TUMORS – 
 
MANAGEMENT IN A  
 
TERTIARY CARE 
CENTRE – A STUDY 
                                                                INDEX TO MASTER CHART 
Sw       -       Swelling                                                                         SCC        
-        Squamous cell carcinoma 
H         -       Hard  MBC      
-        Meibomian carcinoma 
F          -       Firm SC          
-        Sebaceous cyst 
S          -       Soft Hem       
-        Hemangioma 
Tr        -       Trauma PG          
-        Pyogenic granuloma 
In        -        Indurated  Moll       
-        Molluscum 
DC      -        Discoloured Der         
-        Dermoid 
Gr        -       Growth NF          
-        Neurofibroma 
Ul        -        Ulcer Pap         
-        Papilloma 
UL       -        Upper lid Nev        
-        Nevus 
LL       -        Lower lid  (+)          
-        Present 
C         -        Canthus (-)           
-        Absent 
M        -        Margin Ex           
-        Excision 
N        -         Normal LC          
-        Lateral cantholysis 
Pt        -         Ptosis M.s         
-        Marginal shave excision 
Ect      -         Ectropion TLAF     
-        Tenzel lateral adv flap 
Ma      -         Madrosis MF         
-         Mustarde’ s flap 
Con     -        Conjunctiva Cu.B       
-        Cutler Beard 
Bo       -        Bone  Gl.f         
-        Glabellar flap 
 Or       -        Orbit PC           
-        Primary closure 
Sk       -        Skin RT           
-        Radiotherapy 
PA      -         Preauricular CT           
-        Chemotherapy 
SM     -         Submandibular EX           
-        Exenteration 
BCC   -         Basal cell carcinoma ST            
-       Steroids 
 
 
  
 
 LIST OF SURGERIES PERFORMED 
 
Sl. 
No. 
Name Age 
Se
x 
Hosp. 
No. 
Diagnosis Surgery 
1. Kannan 20 M 6980 LE - Corneal tear Wound repair 
2. Kumari 60 F 49501 RE - Corneo scleral 
tear with uveal prolapse
 
Wound repair 
3. Shanmugam 59 M 40701
1 
RE - Immature cataract  SICS with IOL 
implantation 
4. Lakshmi 45 F 40054
9 
RE - Immature cataract SICS with IOL 
implantation 
5. Manjula 45 F 19618 LE-Chronic 
dacryocystitis 
Dacryocystorhinost
omy 
6. Kavitha 25 F 29302 RE - Pterygium  Excision with 
Autograft  
 7. Ramani 35 F 48284 LE - Pterygium  Excision with 
Autograft 
8. Manjula 6 F 48287 LE - Lower lid tear Wound repair 
9. Karthik 12 M 64493 RE - Upper lid tear Wound repair 
10. Rajaram 71 M 70225 LE - Lagophthalmos  Lateral tarsorraphy 
11. Jayalingam 35 M 40586 RE - Panophthalmitis Evisceration  
12. Bharathi 60 F 40601
3 
LE - Chronic 
dacryocystitis 
Dacryocystectomy  
13. Tiripuram 70 F 40581
7 
LE - Non healing ulcer Therapeutic 
keratoplasty 
14. Kannan 60 M 40330
3 
LE - Non healing ulcer Therapeutic 
keratoplasty 
15. Saroja 45 F 40251
0 
LE - Immature cataract SICS with IOL  
16. Ramesh 26 M 40679
9 
RE - Immature cataract SICS with IOL  
17. Ranijitham 50 F 40685
4 
LE - Immature cataract SICS with IOL 
implantation 
18. Shakthi 29 F 39246 LE - Cystic Pterygium Excision with 
autograft 
19. Subramani 49 M 50406 RE - Conj. tear Wound repair 
20. Kuppu 40 F 40446
0 
LE - Mature cataract SICS with IOL 
implantation 
 21. Vinayagam 65 M 40445
4 
RE - Nuclear cataract SICS with IOL  
 
